-
公开(公告)号：KR1020130111448A
公开(公告)日：2013-10-10
申请号：KR1020130034471
申请日：2013-03-29
Applicant: 가톨릭대학교 산학협력단
IPC: C12N15/861 , A61K35/12 , A61P37/00
Abstract: PURPOSE: A composition containing mesenchymal stem cells for treating autoimmune diseases is provided to improve immunity and to prevent dermatitis which is a side effect of a steroid formulation, thereby being used as a safety therapeutic agent for treating autoimmune diseases. CONSTITUTION: A composition for treating autoimmune diseases contains mesenchymal stem cells. The composition treats autoimmune diseases by promoting the generation or activation of regulatory B cells or suppressing the generation of antibody producing B cells. The regulatory B cells are B reg or B10 cells. The B cells are CD19+CD1d+CD5+ B cells or marginal zone B cells.
Abstract translation: 目的：提供一种含有间充质干细胞用于治疗自身免疫性疾病的组合物，用于提高免疫力，防止作为类固醇制剂的副作用的皮炎，从而用作治疗自身免疫疾病的安全治疗剂。 构成：用于治疗自身免疫性疾病的组合物含有间充质干细胞。 组合物通过促进调节性B细胞的产生或活化或抑制产生抗体的B细胞来治疗自身免疫性疾病。 调节性B细胞是B reg或B10细胞。 B细胞是CD19 + CD1d + CD5 + B细胞或边缘区B细胞。
-
202.发明公开
公开(公告)号：KR1020130106320A
公开(公告)日：2013-09-27
申请号：KR1020130028981
申请日：2013-03-19
Applicant: 가톨릭대학교 산학협력단
Abstract: PURPOSE: A composition containing myeloid derived suppressor cells as active ingredients for preventing or treating transplant rejection or autoimmune diseases is provided to promote generation of regulatory B cells and activation of antibody-producing B cells, thereby treating immune diseases including autoimmune diseases. CONSTITUTION: A composition for preventing or treating transplant rejection or autoimmune diseases contains myeloid derived suppressor cells. Myeloid derived suppressor cells are isolated and differentiated from bone marrow of an individual with immune diseases. The composition promotes generation of regulatory B cells or suppresses activation of antibody-producing B cells. Myeloid derived suppressor cells are differentiated by GM-CSF or M-CSF. Myeloid derived suppressor cells have CD11b^+Gr-1^+ marker by induction of differentiation.
Abstract translation: 目的：提供含有骨髓来源的抑制细胞作为预防或治疗移植排斥反应或自身免疫性疾病的活性成分的组合物，以促进调节性B细胞的产生和产生抗体的B细胞的活化，从而治疗包括自身免疫疾病在内的免疫疾病。 构成：用于预防或治疗移植排斥反应或自身免疫性疾病的组合物含有骨髓来源的抑制细胞。 骨髓来源的抑制细胞被分离并与具有免疫疾病的个体的骨髓分化。 该组合物促进调节性B细胞的产生或抑制产生抗体的B细胞的活化。 髓系衍生的抑制细胞被GM-CSF或M-CSF分化。 骨髓衍生抑制细胞通过诱导分化具有CD11b ^ + Gr-1 ^ +标记。
-
公开(公告)号：KR1020130105545A
公开(公告)日：2013-09-25
申请号：KR1020130028183
申请日：2013-03-15
Applicant: 가톨릭대학교 산학협력단
Abstract: PURPOSE: An ROR alpha is provided to suppress the activation of Th17 cells and to regulate immune response, thereby effectively treating and preventing various allergic diseases or autoimmune diseases. CONSTITUTION: A method for reducing the activation of Th17 cells comprises the step of promoting the expression or activation of ROR alpha by transducing a recombinant expression vector containing ROR alpha genes into Th17 cells. ROR alpha gene has a sequence of sequence number 11 or 12. The recombinant expression vector contains a promoter or an enhancer which promotes the expression or activation of ROR alpha. A composition for preventing and treating Th17 cell activation-related diseases contains an agent for promoting the expression or activation of ROR alpha; or Th17 cells in which the agent is transduced, as an active ingredient.
Abstract translation: 目的：提供RORα以抑制Th17细胞的活化并调节免疫应答，从而有效治疗和预防各种过敏性疾病或自身免疫性疾病。 构成：减少Th17细胞活化的方法包括通过将含有RORα基因的重组表达载体转导入Th17细胞来促进RORα的表达或活化的步骤。 RORα基因具有序列号11或12的序列。重组表达载体含有促进RORα表达或活化的启动子或增强子。 用于预防和治疗Th17细胞活化相关疾病的组合物含有促进RORα的表达或活化的药剂; 或Th17细胞作为活性成分。
-
204.发明公开세포투과성을 갖는 Ｒ12 -ＰＩＡＳ3 융합 펩타이드 및 이를 유효성분으로 함유하는 면역질환의 예방 또는 치료용 조성물 审中-实审具有用于预防或治疗免疫疾病的细胞穿透的R12-PIAS3融合肽和包含其的药物组合物
公开(公告)号：KR1020130090055A
公开(公告)日：2013-08-13
申请号：KR1020120011093
申请日：2012-02-03
Applicant: 가톨릭대학교 산학협력단
CPC classification number: C07K14/4703 , A61K38/1709 , A61K47/64 , C07K7/08 , C07K2319/03
Abstract: PURPOSE: R12-PIAS3 fusion peptide is provided to be usefully used as an immune suppressant or a pharmaceutical composition which prevents or treats immune disease including autoimmune disease due to the dysregulation of an immune reaction, inflammation disease and transplantation rejection disease. CONSTITUTION: Recombinant peptide in which twelve successive arginene (R) and PIAS3 are fused is provided. The recombinant peptide has an amino acid sequence represented by a sequence number 1. A vector includes a base sequence coding the peptide. The base sequence comprises a base sequence represented by a sequence number 2. A composition for prevention or treatment of immune disease includes the peptide.
Abstract translation: 目的：提供R12-PIAS3融合肽有效地用作免疫抑制剂或药物组合物，其可防止或治疗由于免疫反应失调引起的自身免疫疾病，炎症疾病和移植排斥疾病的免疫疾病。 构成：提供其中十二个连续的精氨酸（R）和PIAS3融合的重组肽。 重组肽具有由序列号1表示的氨基酸序列。载体包括编码该肽的碱基序列。 碱基序列包含由序列号2表示的碱基序列。用于预防或治疗免疫疾病的组合物包括该肽。
-
205.发明公开간엽줄기세포 및 ⅠＬ-21 차단제를 포함하는 이식편대숙주질환의 예방 또는 치료용 조성물 有权用于预防或治疗包含MESENCHYMAL STEM细胞和IL-21抑制剂的GRAFT-VERSUS-HOST疾病的组合物
公开(公告)号：KR1020130032465A
公开(公告)日：2013-04-02
申请号：KR1020110096057
申请日：2011-09-23
Applicant: 가톨릭대학교 산학협력단
CPC classification number: A61K48/00 , A61K35/28 , A61K48/005 , A61K48/0075
Abstract: PURPOSE: A cell therapeutic composition is provided to effectively suppress immune rejection from a transplant process, and to prevent or treat graft-versus-host disease. CONSTITUTION: A pharmaceutical composition for preventing or treating graft-versus-host disease contains 1ug/ul-3ug/ul of genes which suppresses an IL-21 receptor and 2x10^5-2x10^7 mesenchymal stem cells as an active ingredient. The mesenchymal stem cells are derived from human.
Abstract translation: 目的：提供细胞治疗组合物以有效抑制移植过程的免疫排斥，并预防或治疗移植物抗宿主病。 构成：用于预防或治疗移植物抗宿主病的药物组合物含有1ug / ul-3ug / ul的基因，其抑制IL-21受体和2×10 ^ 5-2×10 ^ 7间充质干细胞作为活性成分。 间充质干细胞来源于人。
-
Patent Agency Ranking
公开(公告)号：KR1020120118978A
公开(公告)日：2012-10-30
申请号：KR1020110036667
申请日：2011-04-20
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/428 , A61K38/17 , A61P19/02 , A61P17/00
CPC classification number: A61K38/1758 , Y10S514/885 , Y10S530/868
Abstract: PURPOSE: A composition for preventing or treating immunization diseases including P53 is provided to suppress inflammatory cytokine IL-17 which causes the immunization diseases. CONSTITUTION: A composition for preventing or treating immunization diseases includes P53 as an active ingredient. The P53 has the activity of preventing or treating the immunization diseases through the formation inhibition of the inflammatory cytokine. The inflammatory cytokine is IL-17. The composition additionally includes substances for promoting the express of the p53 or for promoting the activity of protein. The composition for preventing or treating includes polynucleotide which codes the P53. The polynucleotide ciphering the p53 protein is provided in a recombinant vector type which is connected to a vector which expresses the same. The expression vector which expresses the P53 protein is a non-virus vector or a viral vector.
Abstract translation: 目的：提供用于预防或治疗包括P53在内的免疫疾病的组合物，以抑制引起免疫疾病的炎性细胞因子IL-17。 构成：用于预防或治疗免疫疾病的组合物包括P53作为活性成分。 P53具有通过炎性细胞因子的形成抑制来预防或治疗免疫疾病的活性。 炎性细胞因子是IL-17。 该组合物还包括用于促进p53表达或促进蛋白质活性的物质。 用于预防或治疗的组合物包括编码P53的多核苷酸。 加密p53蛋白质的多核苷酸以连接到表达相同的载体的重组载体类型提供。 表达P53蛋白的表达载体是非病毒载体或病毒载体。
-
公开(公告)号：KR1020120095063A
公开(公告)日：2012-08-28
申请号：KR1020110014466
申请日：2011-02-18
Applicant: 가톨릭대학교 산학협력단
CPC classification number: A61K38/1758 , A61K38/20 , C07K14/4713 , C07K14/4746
Abstract: PURPOSE: A composition for preventing or treating immunization diseases including p53 induced by il-27 is provided to increase expression of p53 by getting stimulation of the IL-27 and to enhance arthritis in animal models according to the expression of p53. CONSTITUTION: A composition for preventing or treating immunization diseases includes p53. The p53 has amino acid sequence described in the sequence number 1(SEQ ID NO:1) or 2. The composition additionally includes the interleukin-27(IL-27). The interleukin-27(IL-27) multiplies the activities of the gene expression of p53 or the p53 protein. The composition for preventing or treating immunization diseases includes a promoter and a vector containing polynucleotide which codes the p53. The polynucleotide has the base sequence described in the sequence number 3 or 4.
Abstract translation: 目的：提供一种用于预防或治疗由il-27诱导的免疫疾病包括p53的组合物，以通过刺激IL-27并根据p53的表达增强动物模型中的关节炎来增加p53的表达。 构成：用于预防或治疗免疫疾病的组合物包括p53。 p53具有序列号1（SEQ ID NO：1）或2所述的氨基酸序列。该组合物另外包括白细胞介素-27（IL-27）。 白介素-27（IL-27）将p53或p53蛋白的基因表达的活性相乘。 用于预防或治疗免疫疾病的组合物包括编码p53的启动子和含有多核苷酸的载体。 多核苷酸具有序列号3或4中描述的碱基序列。
-
公开(公告)号：KR1020120029342A
公开(公告)日：2012-03-26
申请号：KR1020110092596
申请日：2011-09-14
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/225 , A61K31/21 , A61P35/00
Abstract: PURPOSE: A composition containing retinal for preventing or treating cancer or immune diseases is provided to enhance immune-modulating T cell activity. CONSTITUTION: A composition for preventing or treating cancer or immune disease contains retinal compounds of pharmaceutically acceptable salt thereof as an active ingredient. The retinal promotes or enhances regulatory T cell activity or proliferation. A method for reducing or suppressing differentiation of immature T cell into Th17 cell in vitro comprises a step of treating retinal compound or pharmaceutically acceptable salt to the undifferentiated T cells.
Abstract translation: 目的：提供含有用于预防或治疗癌症或免疫疾病的视网膜的组合物，以增强免疫调节T细胞活性。 构成：用于预防或治疗癌症或免疫疾病的组合物含有其药学上可接受的盐的视黄醛化合物作为活性成分。 视网膜促进或增强调节性T细胞活性或增殖。 用于在体外降低或抑制未成熟T细胞分化成Th17细胞的方法包括将视黄醛化合物或药学上可接受的盐处理至未分化的T细胞的步骤。
-
公开(公告)号：KR101099021B1
公开(公告)日：2011-12-28
申请号：KR1020090035796
申请日：2009-04-24
Applicant: 가톨릭대학교 산학협력단 , 에이치 엘 지노믹스(주)
CPC classification number: A61K36/87
Abstract: 본 발명은 유럽종 포도(
Vitis vinifera )의 씨 추출물 및 약학적으로 허용가능한 담체를 포함하는 골관절염(osteoarthritis)의 예방 또는 치료용 약학 조성물을 제공한다.
유럽종 포도의 씨 추출물, 골관절염-
公开(公告)号：KR101096574B1
公开(公告)日：2011-12-20
申请号：KR1020080126216
申请日：2008-12-12
Applicant: 가톨릭대학교 산학협력단 , 에이치 엘 지노믹스(주)
CPC classification number: A61K36/87
Abstract: 본 발명은 유럽종 포도(
Vitis vinifera )의 씨 추출물 및 약제학적으로 허용가능한 담체를 포함하는 골다공증의 예방 또는 치료용 약학 조성물을 제공한다.
유럽종 포도, 골다공증
-
-
-
-
-
-
-
-
-
Search Results
262
records
(took 0.043 seconds)
